在庫拠点

New Jersey, USA
Czech Republic, EU
Mumbai, India

* 在庫状況によります

Documentation

MSDSをダウンロード

サンプルCOAをダウンロード

内容: HPLC、MASS/LC-MS、1H NMR、FT-IR、含量、構造解析レポート（SER）、および製品に応じた追加分析データ。

154229-20-6Anhydro Abiraterone

● Under Development

カタログ番号:	VL830016
CAS番号:	154229-20-6
分子式:	C24H29N
分子量:	331.5 g/mol

ご用件は何ですか?

RFQリストに追加

に関する追加情報 CAS 154229-20-6

親薬物

Abiraterone

IUPAC名

3-((8R, 9S, 10R, 13S, 14S)-10, 13-Dimethyl-2, 7, 8, 9, 10, 11, 12, 13, 14, 15-decahydro-1H-cyclopenta[a]phenanthren-17-yl)pyridine

薬局方同義語

N/A

Other Synonyms

N/A

SMILES

C[C@@]12C(C3=CC=CN=C3)=CC[C@@]1([H])[C@]4([H])CC=C5C=CCC[C@]5(C)[C@@]4([H])CC2

InChI

InChI=1S/C24H29N/c1-23-13-4-3-7-18(23)8-9-19-21-11-10-20(17-6-5-15-25-16-17)24(21,2)14-12-22(19)23/h3,5-8,10,15-16,19,21-22H,4,9,11-14H2,1-2H3/t19-,21-,22-,23-,24+/m0/s1

説明

The compound Anhydro Abiraterone is a thoroughly characterized reference standard that complies with rigorous regulatory guidelines, including those from USP, EMA, JP, and BP. It is ideal for critical applications such as analytical method development, method validation (AMV), and quality control (QC), especially in the production of Abiraterone. Designed to support both Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA), this product delivers the precision required for reliable results. Additionally, it includes a detailed Structure Elucidation Report (SER), ensuring accuracy and dependability for advanced analytical purposes. Anhydro Abiraterone (CAS No: 154229-20-6) is an impurity formed during the synthesis of Abiraterone acetate which is a derivative of steroidal progesterone. It is classified as an adrenal inhibitor, used for hormonal therapy for advanced prostate and breast cancer.

References

Kavitapu, DasameswaraRao, et al. â€œNew Stability Indicating RP-HPLC Method for the Determination of Abiraterone Acetate, Its Related Substances and Degradation Products in Bulk and Dosage Form.â€ Materials Today: Proceedings, vol. 34, 2021, pp. 469â€“78, https://doi.org/10.1016/j.matpr.2020.02.665. ?